tirzepatide family The GLP-1 family, explained for researchers: Semaglutide, Tirzepatide, Retatrutide — what they are and the receptor research context. Note: Retatrutide is investigational (Phase 3). No weight-loss or human-effect claims here — just Tirzepatide (Mounjaro) for the Treatment

10.1038/psp.2014.45 [DOI] [PMC free article] [PubMed] [Google Scholar] Malik P., Edginton A

It is being studied for obesity, T2D, MASLD, obstructive sleep apnea, and knee osteoarthritis linked to obesity.[4] Eli Lilly began developing retatrutide after the early commercial success of tirzepatide (the dual-agonist molecule that became Mounjaro and Zepbound) signaled that adding more hormone-receptor targets to a single molecule could push weight loss meaningfully higher than what a GLP-1 drug alone could deliver

Among these trials are the STEP (Semaglutide Treatment Effect in People with Obesity) series of RCTs

Allow the medication to reach room temperature before injection if refrigerated

Enter your dose, injection day, and schedule to see how drug levels build, plateau at steady state, and decline after stopping

It works by: Increasing beta-endorphins , which support a higher metabolic rate